Coya Therapeutics Fortifies ALS Fight with Cash and Clinical Progress

HOUSTON, TX – August 11, 2026 – In a landscape desperate for breakthroughs in neurodegenerative disease, Coya Therapeutics (NASDAQ: COYA) today signaled robust and sustained momentum, reporting second-quarter financial results that underscore a strategy of disciplined execution and clinical advancement. The Houston-based biotech highlighted significant progress in its lead program, COYA 302, for Amyotrophic Lateral Sclerosis (ALS), backed by a healthy cash runway and plans to expand its innovative immune-modulating therapy into a new trial for Frontotemporal Dementia (FTD).

This quarter’s update paints a picture of a company methodically hitting its milestones, from advancing its pivotal Phase 2 ALSTARS trial to securing a coveted FDA Fast Track Designation. For investors and patient communities alike, Coya’s progress represents a calculated push to translate a novel scientific hypothesis—that rebalancing the body’s immune system can fight devastating brain and nerve diseases—into a tangible therapeutic reality.

Clinical Momentum and Strategic Validation

The centerpiece of Coya's strategy is COYA 302, and its path through the clinic is being closely watched. The company confirmed that enrollment in its Phase 2 ALSTARS trial for ALS is proceeding on schedule, with expectations to complete enrollment in the second half of this year. This sets the stage for a highly anticipated topline data readout in the first quarter of 2027.

“During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.”

Significantly, the first group of patients in the study has already moved into a 24-week blinded active treatment extension, a positive indicator of trial progression. This progress is further buoyed by the FDA’s decision to grant COYA 302 Fast Track Designation for ALS. More than just an accolade, this designation is a critical strategic tool intended to expedite the development and review of drugs that address serious, unmet medical needs. It opens the door to more frequent communication with the FDA and the potential for a rolling review of the company's future marketing application, potentially shortening the timeline to get the therapy to patients if proven successful.

The Science of Immune Rebalancing

Coya’s approach moves beyond traditional neurology, targeting the intersection of the immune system and the nervous system. A growing body of evidence suggests that in diseases like ALS and FTD, the immune system goes awry. Specifically, a critical group of peace-keeping cells called regulatory T-cells (Tregs) become dysfunctional, allowing inflammation to run rampant and damage neurons.

COYA 302 is designed to tackle this problem with a dual-pronged approach. The therapy combines a low dose of Interleukin-2 (LD IL-2) to boost the number and function of protective Tregs, with CTLA-4 Ig, a biologic that suppresses the activity of inflammatory cells. The strategy is not just to reduce inflammation, but to restore the immune system’s natural balance. This mechanistic rationale was recently supported by a publication in the peer-reviewed journal Annals of Clinical and Translational Neurology, which demonstrated a correlation between key biomarkers and clinical outcomes in ALS patients, lending scientific weight to the company’s therapeutic hypothesis.

A Calculated Expansion Beyond ALS

Demonstrating a broader vision for its platform, Coya is not limiting its focus to ALS. The company announced its plan to initiate a Phase 2 study of COYA 302 for Frontotemporal Dementia (FTD) in the coming months. FTD, a devastating cause of dementia in younger patients, currently has no approved disease-modifying treatments, representing another area of profound unmet need.

The strategic rationale is clear: like ALS, FTD is characterized by significant neuroinflammation, and early data from an investigator-initiated study has already shown that Coya’s therapeutic concept could enhance Treg function and provide cognitive stability in FTD patients. This expansion is a key strategic shift, positioning Coya not as a single-disease company, but as a leader in a new class of therapies targeting neuroinflammation across multiple disorders.

“The progress we have made in the ALSTARS trial continues to reinforce our confidence in COYA 302 as we advance this program for people living with ALS,” said Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya. “We are grateful to the patients, families, and investigators whose partnership makes this work possible.”

Financial Fortitude for the Path Ahead

For any clinical-stage biotech, ambition must be backed by capital. Coya’s second-quarter report shows a company in a strong financial position to execute its plans. The company ended the quarter with $43.2 million in cash and cash equivalents, which it projects is sufficient to fund operations past the crucial ALSTARS data readout and into the second half of 2027.

While the company reported a net loss of $6.6 million for the quarter, this is typical for a biotech investing heavily in development. In fact, the increase in research and development expenses—to $5.0 million from $3.7 million in the same period last year—is a direct reflection of the costs associated with advancing the Phase 2 ALS trial. This spending is a sign of progress, not profligacy, especially when paired with a slight decrease in general and administrative expenses, suggesting a disciplined approach to capital allocation.

With a clear set of upcoming milestones for the remainder of 2026—including completing ALSTARS enrollment, initiating the FTD trial, and announcing additional biomarker data—Coya Therapeutics is building a compelling case that its strategic shifts are paving a clear path toward potential growth and, more importantly, potential new hope for patients with neurodegenerative diseases.